Ozeki et al (2022) found that GLP1-RA semaglutide effectively reduces body adiposity while maintaining the skeletal muscle mass in obese Type 2 Diabetic patients. Xiang et al (2023) had similar findings, semaglutide can reduce the weight and fat of obese patients while effectively maintaining muscle mass and muscle strength. Chen et al (2023) conducted a 3-month intervention using dulaglutide in patients with Type 2 Diabetes, noting , dulaglutide intervention does not cause muscle and bone mass loss while inducing weight loss, and % change in body fat was independently associated with improved glucose control during dulaglutide therapy. With an increasing number of physicians and researchers relying on GLP-1 therapies for clinical care and research, it will continue to be crucial to track sensitive changes in body composition across different patient populations

2 Understanding Acute versus Chronic Constipation In general, many people experience acute constipation due to a change in diet, medications, or lifestyle
According to the results from in vitro and in vivo studies, tanshinone IIA pretreatment protects the liver from APAP-induced liver injury by activating Nrf2 and increasing the mRNA and protein levels of the Nrf2 target genes glutamate-cysteine ligase catalytic subunit (GCLC), NQO1, and HO-1 (Wang et al., 2016)
As your bodys master antioxidant, it helps protect skin from oxidative damage and promotes a clear complexion